Acologix has filed to go public with an IPO designed to raise $115 million. The drug developer has programs in renal diseases like chronic kidney disease and hard tissue ailments. The Hayward, CA-based biotech recently completed a Phase II feasibility study of AC-100 for the treatment of periodontal defects, which failed to hit its endpoint for significant regeneration of more periodontal bone versus a placebo. Researchers blamed the dosage used in the trial.
- here's the MarketWatch report